Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights

Journal of Hematology and Oncology

Volumn 3, Issue , 2010, Pages

  Zhu, Xiongpeng ^a,b   Ma, Yuehua ^b   Liu, Delong ^b  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AMONAFIDE; ANTHRACYCLINE; ANTILEUKEMIC AGENT; AS 1413; AZACITIDINE; BEHENOYLARA C; BORTEZOMIB; CD135 ANTIGEN; CD33 ANTIGEN; CLOFARABINE; CORE BINDING FACTOR; CPX 351; CYTARABINE; DAUNORUBICIN; DNA METHYLTRANSFERASE INHIBITOR; ETOPOSIDE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; LENALIDOMIDE; MITOXANTRONE; NUCLEOSIDE ANALOG; PROTEIN FARNESYLTRANSFERASE INHIBITOR; SORAFENIB; TIPIFARNIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORELOXIN; VORINOSTAT; ANTINEOPLASTIC AGENT;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; AGE; ALLOGENEIC STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE SEQUENCE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENCAPSULATION; EVENT FREE SURVIVAL; GENE DUPLICATION; HUMAN; INTERNAL TANDEM DUPLICATION; KARYOTYPE; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LIPOSOMAL DELIVERY; LOW DRUG DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; OPTIMAL DRUG DOSE; OVERALL SURVIVAL; REVIEW; UNSPECIFIED SIDE EFFECT; ORGANIZATION;

ANTINEOPLASTIC AGENTS; CONGRESSES AS TOPIC; HUMANS; LEUKEMIA, MYELOID, ACUTE;

EID: 77951111333     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-3-17     Document Type: Review

References (57)

1. A comparative study of two different doses of cytarabine for acute myeloid leukemia: a phase III trial of Cancer and Leukemia Group B. RO Dillman RB Davis MR Green RB Weiss AJ Gottlieb S Caplan,, et al. Blood 1991 78 2520 2526 1824249
2. Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia? RA Larson, Leukemia 2003 17 488 491 10.1038/sj.leu.2402809 12646935
3. Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621. JE Kolitz SL George RK Dodge DD Hurd BL Powell SL Allen,, et al. J Clin Oncol 2004 22 4290 4301 10.1200/JCO.2004.11.106 15514371
4. Randomized Study of Intensified Anthracycline Doses for Induction and Recombinant Interleukin-2 for Maintenance in Patients With Acute Myeloid Leukemia Age 50 to 70 Years: Results of the ALFA-9801 Study. C Pautas F Merabet X Thomas E Raffoux C Gardin S Corm,, et al. J Clin Oncol 2010 28 808 814 10.1200/JCO.2009.23.2652 20048183
5. Anthracycline dose intensification in acute myeloid leukemia. HF Fernandez Z Sun X Yao MR Litzow SM Luger EM Paietta,, et al. N Engl J Med 2009 361 1249 1259 10.1056/NEJMoa0904544 19776406
6. High-dose daunorubicin in older patients with acute myeloid leukemia. B Lowenberg GJ Ossenkoppele W van Putten HC Schouten C Graux A Ferrant,, et al. N Engl J Med 2009 361 1235 1248 10.1056/NEJMoa0901409 19776405
7. Optimal induction and post-remission therapy for AML in first remission. JM Rowe, Hematology 2009 2009 396 405 10.1182/asheducation-2009.1.396
8. Phase I Study of a Liposomal Carrier (CPX-351) Containing a Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in Advanced Leukemias. EJ Feldman J Lancet JE Kolitz E Ritchie AF List E Asatiani,, et al. Blood 2008 112 abstract no. 2984. 18716130
9. Phase IIb Randomized Study of CPX-351 Vs. Conventional Cytarabine + Daunorubicin in Newly Diagnosed AML Patients Aged 60-75: Safety Report. JE Lancet E J Feldman J E Kolitz M S Tallman D E Hogge R S Komrokji,, et al. Blood 2009 114 bstract No1033
10. A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. WJ Kell AK Burnett R Chopra JAL Yin RE Clark A Rohatiner,, et al. Blood 2003 102 4277 4283 10.1182/blood-2003-05-1620 12933575
11. The Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy for AML Improves Disease Free Survival without Extra Toxicity: Preliminary Analysis of 1115 Patients in the MRC AML15 Trial. AK Burnett W Kell AH Goldstone, Blood 2006 108 Abstract No. 13.
12. Clinical and Molecular Response in Core Binding Factor Acute Myelogenous Leukemia with Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin. G Borthakur S Faderl S Verstovsek D Jones V Gandhi Z Estrov,, et al. Blood 2009 114 Abstract No.2056.
13. Four Drugs Induction Therapy (fludarabine, cytarabine, idarubicin and gemtuzumab ozogamycin) for the Treatment of Elderly Acute Myeloid Leukemia Patients. S Paolini S Parisi A Candoni PP Piccaluga M Gottardi C Laterza,, et al. Blood 2009 114 Abstract No.1027.
14. High Dose Cytarabine (HiDAC) and Mitoxantrone (MITO) Is An Effective Induction Therapy for High-Risk Acute Myeloid Leukemia. S Larson N Campbell D Huo A Artz Y Zhang D Gajria,, et al. Blood 2009 114 Abstract No.1048.
15. Phase 2 Study of FLAGM (Fludarabine+High-Dose Ara-C +G-CSF+Mitoxantrone) for Relapsed or Refractory Acute Myeloid Leukemia (AML): A Report From the Japan Adult Leukemia Study Group (JALSG). S Miyawaki N Hatsumi T Yamauchi, Blood 2009 114 Abstract No.1058.
16. A Direct comparison of high dose cytarabineto combination of gemtuzumab and high dose cytarabine for acute myeloid leukemia patients in first relapse confirmed the benefit of gemtuzumab based regimens. t prébet a charbonnier a etienne e d'incan s fürst d blaise, blood 2009 114 abstract no.2051.
17. High Dose Cytarabine, Clofarabine and Gemtuzumab Ozogamicin (CLAC-MYL) in Relapsed or Refractory AML Patients. B Scappini G Gianfaldoni P Salvatore M C Susini T Izzo F Mannelli,, et al. Blood 2009 114 Abstract No.1060.
18. Single-Agent Clofarabine Produces Durable Remissions in Patients with Acute Myelogenous Leukemia (AML) Who Are = 70, Have Intermediate or Unfavorable Cytogenetics, Antecedent Hematological Disorders (AHD), or 2 or More Unfavorable Prognostic Factors. HP Erba S Faderl D F Claxton M Arellano R M Lyons T J Kovacsovics,, et al. Blood 2009 114 Abstract No.2083.
19. G-CSF Priming, Clofarabine and High Dose Cytarabine (GCLAC) for Relapsed or Refractory Acute Myeloid Leukemia (AML). PS Becker E Estey S Petersdorf B E Storer F R Appelbaum, Blood 2009 114 Abstract No.2068. 10.1182/blood-2009-02- 206730
20. A Phase I, Dose Escalation Study of Clofarabine in Combination with Fractionated Gemtuzumab Ozogamicin in Relapsed and Refractory Acute Myeloid Leukemia (AML). MC Foster C Amin P M Voorhees H W Van Deventer K L Richards I Anastasia,, et al. Blood 2009 114 Abstract No.2048. 19564639
21. Clofarabine Plus Low-Dose Cytarabine Induction Followed by Consolidation with Clofarabine Plus Low-Dose Cytarabine Alternating with Decitabine as Frontline Therapy for Patients (pts) with Acute Myeloid Leukemia (AML) = 60 Years (yrs). SA Parikh K Hagop G Garcia-Manero E Jabbour T Kadia F Ravandi,, et al. Blood 2009 114 Abstract No.2058.
22. A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, in Elderly Patients with AML Previously Untreated or in First Relapse. HM Kantarjian G Garcia-Manero S Luger P Venugopal L J Maness M Wetzler,, et al. Blood 2009 114 Abstract No.1061.
23. APhase II Multicentre Study with Elacytarabine as Second Salvage Therapyin Patients with AML. S O'Brien D A Rizzieri N Vey F Ravandi U O Krug M A Sekeres,, et al. Blood 2009 114 Abstract No.1042.
24. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. TK Gregory D Wald Y Chen JM Vermaat Y Xiong W Tse, J Hematol Oncol 2009 2 23 10.1186/1756-8722-2-23 19490647
25. Compassionate Use of Sorafenib in Relapsed and Refractory Flt3-ITD Positive Acute Myeloid Leukemia. S Metzelder S Scholl K Matthias A Reiter R G Meyer T Heinicke,, et al. Blood 2009 114 Abstract No.2060.
26. FLT3 Inhibitor Therapy for Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML): Impact On Survival According to FLT3 Status. N Pemmaraju H M Kantarjian F Ravandi G Garcia-Manero B Gautam S A Parikh,, et al. Blood 2009 114 Abstract No. 1026.
27. Clinical Efficacy of Sorafenib in Patients with Acute Myeloid Leukemia (AML) and Activating FLT3-Mutations. T Schroeder C Saure I Bruns F Zohren A G Czibere N N Safaian,, et al. Blood 2009 114 Abstract No.2057. 19779039
28. Patterns of Molecular Response to and Relapse After Combination of Sorafenib, Idarubicin, and Cytarabine in Patients with Newly Diagnosed FLT3-Mutant Acute Myeloid Leukemia (AML). A Al-Kali D Jones J Cortes S Faderl A Xue G Garcia-Manero,, et al. Blood 2009 114 Abstract No.2079.
29. Effect of Ras Inhibition in Hematopoiesis and BCR/ABL Leukemogenesis. K Baum R Ren, Journal of Hematology & Oncology 2008 1 5 18577264 10.1186/1756-8722-1-5
30. RASGRP1/APTX Ratio Strongly Correlates with Clinical Response and Survival in AML Patients Treated with Tipifarnib-Bortezomib Combination. S Paolini E Ottaviani S Parisi F Salmi B Lama A Curti,, et al. Blood 2009 114 Abstract No.1028.
31. Evaluation of Alternative, "Low-intensity" Induction Regimens in Elderly Adults with Acute Myeloid Leukemia (AML). EJ Feldman E Ritchie U Gergis S Mayer J M Scandura P J Christos,, et al. Blood 2009 114 Abstract No.2066.
32. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. S Cang Y Ma D Liu, J Hematol Oncol 2009 2 22 10.1186/1756-8722-2-22 19486511
33. Vorinostat in solid and hematologic malignancies. D Siegel M Hussein C Belani F Robert E Galanis VM Richon,, et al. J Hematol Oncol 2009 2 31 10.1186/1756-8722-2-31 19635146
34. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Tan S Cang Y Ma RL Petrillo D Liu, J Hematol Oncol 2010 3 5 10.1186/1756-8722-3-5 20132536
35. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor 2. B Sanchez-Gonzalez H Yang C Bueso-Ramos K Hoshino A Quintas-Cardama VM Richon,, et al. Blood 2006 108 1174 1182 10.1182/blood-2005-09-008086 16675713
36. Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias 1. K Shiozawa T Nakanishi M Tan HB Fang WC Wang MJ Edelman,, et al. Clin Cancer Res 2009 15 1698 1707 10.1158/1078-0432.CCR-08-1587 19223502
37. Phase II Study of Vorinostat in Combination with Idarubicin (Ida) and Cytarabine (ara-C) as Front Line Therapy in Acute Myelogenous Leukemia (AML) or Higher Risk Myelodysplastic Syndrome (MDS). G Garcia-Manero F P Tambaro N B Bekele E Jabbour F Ravandi H Yang,, et al. Blood 2009 114 Abstract No.1055. 19420352
38. Vorinostat in Combination with Decitabine for the Treatment of Relapsed or Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS): A Phase I, Dose-Escalation Study. M Kirschbaum G Ivana S L Goldberg L Kujawski E Atallah P Marks,, et al. Blood 2009 114 Abstract No.2089.
39. Phase 2 Study of Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome-Outcome in Previously Untreated Patients. G Borthakur G Garcia-Manero Z Estrov M Konopleva J A Burger De A Thomas,, et al. Blood 2009 114 Abstract No.1053.
40. Decitabine-Based Salvage Therapy in Adults with Acute Myeloid Leukemia. EK Ritchie J Arnason E J Feldman U S Gergis S A Mayer C Ippoliti,, et al. Blood 2009 114 Abstract No.2063.
41. Azacytidine in Refractory or Relapsed AML After Intensive Chemotherapy (IC): Results of the French ATU Program. R Itzykson S Thepo C Reche J Delaunay B Quesnel, Blood 2009 114 Abstract No.1054.
42. Azacitadine and Low-Dose Gemtuzumab Ozogamicin for the Treatment of Poor-Risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), Including Relapsed, Refractory Disease. LC Michaelis D Shafer K Barton T Rodriguez S Smith P Stiff,, et al. Blood 2009 114 Abstract No.1034.
43. Epigenetic targeting via transcriptional inhibition of dna methyltransferase: a phase i study of bortezomib in combination with 5-azacytidine in adults with relapsed or refractory acute myeloid leukemia (aml). w blum r b klisovic a walker r garzon s liu l j schaaf,, et al. blood 2009 114 abstract no.2065. 19553637
44. A phase i trial of the epigenetic modulators vorinostat, in combination with azacitidine (azac) in patients with the myelodysplastic syndrome (mds) and acute myeloid leukemia (aml): a study of the new york cancer consortium. lr silverman a verma r odchimar-reissig a leblanc v najfeld j gabrilove,, et al. ash annual meeting abstracts 2008 112 3656
45. A Phase 2 Dose Regimen Optimization Study of Three Schedules of Voreloxin as Single Agent Therapy for Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia. F Ravandi H M Kantarjian L D Cripe M Maris M Cooper S R Dakhil,, et al. Blood 2009 114 Abstract No.1037.
46. Amonafide L-Malate (AS1413) in Combination with Cytarabine Is Equally Effective in Older and Younger Patients with Secondary Acute Myeloid Leukemia (AML); Final Data From a Phase II Study. HP Erba M O'Donnell S L Allen M R Baer B L Powell R M Stone,, et al. Blood 2009 114 Abstract No.1047.
47. High Remission Rates and Long-Term Survival in a High Percentage of Patients Achieved by Intensive Chemotherapy for AML and Further Improvement of Supportive Care. T Kyo A Kimura K Kyo N Yoshida H Asaoku K Iwato,, et al. Blood 2009 114 Abstract No.1052.
48. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra(R), TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. A Raza N Galili N Callander L Ochoa L Piro P Emanuel,, et al. J Hematol Oncol 2009 2 20 10.1186/1756-8722-2- 20 19439093
49. Mechanism of action of lenalidomide in hematological malignancies. V Kotla S Goel S Nischal C Heuck K Vivek B Das,, et al. J Hematol Oncol 2009 2 36 10.1186/1756-8722-2-36 19674465
50. Lenalidomide (LEN) Combined to Intensive Chemotherapy (IC) in AML and Higher Risk MDS with Del 5q. Interim Results of a Phase I/II Study. L Ades A Stamatoullas E Raffoux T Prebet P Lenain R Guieze,, et al. Blood 2009 114 Abstract No.1049.
51. Targeting the Oncogene eIF4E with Ribavirin: A Novel Therapeutic Avenue in Acute Myeloid Leukemia. SE Assouline E Cocolakis C Rousseau B Culjkovic N Beslu A Amri,, et al. Blood 2009 114 Abstract No.2085. 10.1182/blood-2009-02- 205153
52. A Phase 1 Dose-Escalation Study of the Novel KSP Inhibitor ARRY-520 in Advanced Leukemias. G Garcia-Manero J H Khoury G Borthakur F Ravandi T Kadia Z Estrov,, et al. Blood 2009 114 Abstract No.2047. 19420352
53. Phase I/II Study to Assess the Safety and Efficacy of the Aurora B Kinase Inhibitor, AZD in Patients with Advanced Acute Myeloid Leukemia. B Lowenberg P Rousselot G Martinelli A Goudie P Stockman H Kantarjian, Blood 1152 114 Abstract No.2080.
54. From basic research to clinical development of MEK1/2 inhibitors for cancer therapy. C Fremin S Meloche, Journal of Hematology & Oncology 2010 3 8 20149254 10.1186/1756-8722-3-8
55. Targeting MEK1/2 signaling cascade by AS70 a novel selective MEK1/2 Inhibitor, induces pleiotropic anti-myeloma activity in vitro and In Vivo. YT Tai K kim XF Li M fulciniti W Song S nahar,, et al. ASH annual Meeting Abstracts 2009 114 3848
56. Phase II Study of the Oral MEK Inhibitor AZD6244 in Advanced Acute Myeloid Leukemia (AML). O Odenike E Curran N Iyengar L Popplewell M Kirschbaum H P Erba,, et al. Blood 2009 114 Abstract No.2081.
57. Phase I Study of the Novel Survivin and cdc2/CDK1 Inhibitor Terameprocol in Patients with Advanced Leukemias. R Tibes K T McDonagh L Lekakis N Frazer S Mohrland B Dawn,, et al. Blood 2009 114 Abstract No.1039.